ea0084ps3-12-112 | Graves’ Disease 2 and Orbitopathy | ETA2022
Di Marco Francesco
, Porcaro Laura
, Crivicich Erica
, Curro Nicola
, Arosio Maura
, Muller Ilaria
, Salvi Mario
Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves disease (GD) accounting for 63-65% of cases. Graves Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...